Virocomb Tablets 150 mg/300 mg: Composition and Product Information

Virocomb Tablets in the 150 mg/300 mg formulation contain lamivudine and zidovudine, two active substances belonging to the nucleoside reverse transcriptase inhibitor (NRTI) class of antiretroviral medicines. The formulation and its approved indications should be confirmed against the specific product's official packaging and product information leaflet.

For pharmaceutical professionals reviewing this product in the Singapore market, accurate identification of the active ingredients, individual strengths, dosage form and regulatory status is essential. Product information should be documented clearly and checked against authoritative records before it is included in a professional pharmaceutical catalogue.

Strength and Composition

Product name: Virocomb Tablets

Dosage form: Oral tablets

Strength: 150 mg/300 mg

Active ingredients: Lamivudine 150 mg and zidovudine 300 mg per tablet

Therapeutic classification: Antiretroviral medicines

Storage: Follow the conditions stated on the official product label.

The strength indicates the quantity of each active ingredient contained in one tablet. Lamivudine and zidovudine act by inhibiting HIV reverse transcriptase, an enzyme involved in viral replication. Their use forms part of an appropriately prescribed antiretroviral treatment regimen.

The precise formulation must be checked before publication because similarly named products may have different compositions. Packaging details, manufacturer information, batch information and expiry dates should be taken directly from the relevant product documentation rather than inferred.

Clinical and Safety Information

The suitability of an antiretroviral regimen depends on individual clinical circumstances, treatment history, other medicines and relevant laboratory findings. Treatment decisions should be made by qualified healthcare professionals.

Potential adverse effects and precautions should be reviewed in the official product information. Lamivudine and zidovudine may be associated with blood-related abnormalities and other adverse effects, and appropriate clinical monitoring may be necessary. The product leaflet should be consulted for complete contraindications, warnings and interaction information.

This product reference does not provide individual treatment instructions and should not replace professional medical assessment.

Singapore Regulatory Considerations

Before representing Virocomb Tablets as available in Singapore, verify the exact product's registration status and applicable import and supply requirements with the Health Sciences Authority (HSA).

A product's presence in overseas pharmaceutical markets does not establish authorisation for sale in Singapore. Any published technical information should be accurate, supported by documentation and consistent with the product's applicable approved information. Public-facing promotion of prescription-only medicines is prohibited under Singapore's applicable advertising requirements.

Frequently Asked Questions

1. What is the strength of Virocomb Tablets?

The 150 mg/300 mg formulation contains 150 mg of lamivudine and 300 mg of zidovudine per tablet.

2. What is the composition?

The listed active ingredients are lamivudine and zidovudine. Confirm the formulation using the specific product label.

3. What is the therapeutic classification?

Both ingredients are nucleoside reverse transcriptase inhibitors used in antiretroviral treatment.

4. What information should be checked before listing the product?

Verify the composition, strength, packaging, official product documentation and applicable regulatory status.

5. How can Singapore registration be verified?

Consult the Health Sciences Authority's official therapeutic product database and relevant import and supply guidance.

Disclaimer: This document is a general product reference for professional review. It is not a substitute for the official product information or clinical advice.